

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 15423

Statement, Robert J. Ledogar, 5/27/76 - 9

- 1) That the United States government take an active role in seeking an international convention on the conditions of trade, sale, marketing, advertising and labelling of pharmaceutical products. I have in mind a role similar to that taken most recently by our government in urging international action on the question of bribery in international business dealings.
- 2) That the United States government support the recommendation of the United Nations Group of Eminent Persons that the affiliates of transnational corporations should be required to reveal to host governments any sales prohibitions and restrictions in manufacturing imposed by home or other host countries with respect to the health and safety of consumers.
- 3) That the United States government, through its representatives to the World Health Organization, support current efforts of that organization to improve its International System of Information on Drugs and look for ways to restructure the Geneva Research Center for Monitoring Adverse Reactions to Drugs so that it may be more suited to the needs of less developed countries.
- 4) That the United States government offer, preferably through multilateral channels, financial and technical assistance, independent of any influence from private U.S. firms, for improving the capacity of